Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Surgery for localized, locally advanced and high risk prostate cancer
1. Steven Joniau, MD, PhD
University Hospitals Leuven
Leuven
Belgium
Surgery for localized, locally advanced and
high risk prostate cancer
2. 117,328 patients with prostate cancer
26,410 low risk (22.5%)
cT1-T2, PSA <10 ng/ml AND Gleason 2-6
26,611 intermediate risk (22.7%)
cT1-T2 AND PSA 10 - <20 OR Gleason 7
30,159 high risk (25.7%)
cT3 or PSA 20-50 or Gleason 8-10
Non-curatively treated
Rider JR et al. Eur Urol 2012
2
Who dies of PCa?
Natural evolution of non-curatively treated PCa
3. 10%
20%
35-40%
Rider JR et al. Eur Urol 2012
All ages <65 years 65-75 years >75 years
Prostate cancer Cardiovascular Other
LowriskMediumriskHighrisk Who dies of PCa?
Natural evolution of non-curatively treated PCa
3
4. Complete removal of the prostate, seminal vesicles, and pelvic
lymph nodes (when necessary)
• With minimal perioperative morbidity, no blood transfusions,
and early return to normal activities
• No positive surgical margins
• No long-term loss of continence or potency
Goals of modern radical prostatectomy (RP)
4
5. PIVOT Trial
PSA detected
RP vs observation for localised PCa
RP did not significantly reduce all-cause or PCa-specific mortality as compared
with observation
WiltTJ et al. N Engl J Med 2012;367:203-13
PCa-specific mortality
5
9. BrigantiA, Spahn M, Joniau S et al. for EMPaCT Eur Urol 2013
Only men ≤ 59 years old had higher risk of PCa-related
death than death-related to other causes
10%
<10%
Prostate cancer Other
MORTALITY RATES FOR SURGICALLY TREATED
HIGH-RISK PCa
10. Cooperberg M, et al.AUA 2015 – Data from CAPSURE
Which treatment for which cancer?
Up untill 2007, Low-risk PCa was too often actively treated,
while high-risk PCa was too often undertreated
10
11. Cooperberg M, et al.AUA 2015 – Data from CAPSURE
11
After 2007, Low-risk PCa was more often treated with AS/WW,
while high-risk PCa was more often actively treated!!!
Which treatment for which cancer?
12. Cumulative incidence function estimates of cancer
specific and other cause mortality survival curves
(n=34 515), stratified according to treatment type.
Sooriakumaran P et al. BMJ 2014;348:bmj.g1502
M+ or N+ orT4 or
PSA>50
Low Intermediate High
RP
RT
12
13. Sooriakumaran P et al. BMJ 2014;348:bmj.g1502
13
Cumulative incidence function estimates of cancer
specific and other cause mortality survival curves
(n=34 515), stratified according to treatment type.
14. Cooperberg M, et al.AUA 2015 – Data from CAPSURE
14
HIGH-RISK
15-YEARCANCERMORTALITY
15. - Retrospective analysis of data from the Norwegian Prostate Cancer Registry, 2004-2005
- 3486 patients, RP (n = 895), EBRT +/- ADT (n = 1339), or no local treatment (n = 1252)
- Clinical stageT1-T3, PSA ≤100 ng/ml, D’Amico risk group stratification
- Comparison of active local treatment (RP, RAD) versus no active local treatment (NoLocTrt)
PCa mortality
Other cause mortality
15
HIGH-RISK
17. • NO difference in positive surgical margins
• NO difference in incontinence
• SMALL difference in erectile dysfunction in favor of RALP
18. The changing role of surgery
• Properly performed, RP is a highly effective treatment
for high-risk prostate cancer in men with a sufficiently
long life expectancy to justify the risks
• Outcomes of RP – cancer control, peri-op complications,
and long-term urinary and sexual function – are directly
related to the skill and experience of the surgeon, but
not to the technology used (open v. robot-assisted)
18